Udenafil: Efficacy and tolerability in the management of erectile dysfunction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, S.G. | - |
dc.contributor.author | Kim, J.J. | - |
dc.date.accessioned | 2021-09-06T09:51:40Z | - |
dc.date.available | 2021-09-06T09:51:40Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1756-2872 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/105925 | - |
dc.description.abstract | Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil's efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil's promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia. © 2012, SAGE Publications. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.subject | avanafil | - |
dc.subject | placebo | - |
dc.subject | sildenafil | - |
dc.subject | tadalafil | - |
dc.subject | udenafil | - |
dc.subject | vardenafil | - |
dc.subject | article | - |
dc.subject | comorbidity | - |
dc.subject | conjunctival hyperemia | - |
dc.subject | diabetes mellitus | - |
dc.subject | drug blood level | - |
dc.subject | drug efficacy | - |
dc.subject | drug tolerability | - |
dc.subject | drug withdrawal | - |
dc.subject | enzyme inhibition | - |
dc.subject | erectile dysfunction | - |
dc.subject | ethnicity | - |
dc.subject | flushing | - |
dc.subject | headache | - |
dc.subject | human | - |
dc.subject | hypertension | - |
dc.subject | maximum plasma concentration | - |
dc.subject | phase 1 clinical trial (topic) | - |
dc.subject | phase 2 clinical trial (topic) | - |
dc.subject | phase 3 clinical trial (topic) | - |
dc.subject | priority journal | - |
dc.subject | prostate hypertrophy | - |
dc.subject | randomized controlled trial (topic) | - |
dc.subject | side effect | - |
dc.subject | single drug dose | - |
dc.subject | time to maximum plasma concentration | - |
dc.title | Udenafil: Efficacy and tolerability in the management of erectile dysfunction | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, S.G. | - |
dc.contributor.affiliatedAuthor | Kim, J.J. | - |
dc.identifier.doi | 10.1177/1756287212470019 | - |
dc.identifier.scopusid | 2-s2.0-84876376281 | - |
dc.identifier.bibliographicCitation | Therapeutic Advances in Urology, v.5, no.2, pp.101 - 110 | - |
dc.relation.isPartOf | Therapeutic Advances in Urology | - |
dc.citation.title | Therapeutic Advances in Urology | - |
dc.citation.volume | 5 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 101 | - |
dc.citation.endPage | 110 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | avanafil | - |
dc.subject.keywordPlus | placebo | - |
dc.subject.keywordPlus | sildenafil | - |
dc.subject.keywordPlus | tadalafil | - |
dc.subject.keywordPlus | udenafil | - |
dc.subject.keywordPlus | vardenafil | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | comorbidity | - |
dc.subject.keywordPlus | conjunctival hyperemia | - |
dc.subject.keywordPlus | diabetes mellitus | - |
dc.subject.keywordPlus | drug blood level | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug tolerability | - |
dc.subject.keywordPlus | drug withdrawal | - |
dc.subject.keywordPlus | enzyme inhibition | - |
dc.subject.keywordPlus | erectile dysfunction | - |
dc.subject.keywordPlus | ethnicity | - |
dc.subject.keywordPlus | flushing | - |
dc.subject.keywordPlus | headache | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | hypertension | - |
dc.subject.keywordPlus | maximum plasma concentration | - |
dc.subject.keywordPlus | phase 1 clinical trial (topic) | - |
dc.subject.keywordPlus | phase 2 clinical trial (topic) | - |
dc.subject.keywordPlus | phase 3 clinical trial (topic) | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | prostate hypertrophy | - |
dc.subject.keywordPlus | randomized controlled trial (topic) | - |
dc.subject.keywordPlus | side effect | - |
dc.subject.keywordPlus | single drug dose | - |
dc.subject.keywordPlus | time to maximum plasma concentration | - |
dc.subject.keywordAuthor | Erectile dysfuction | - |
dc.subject.keywordAuthor | Once-daily dosing | - |
dc.subject.keywordAuthor | Phosphodiesterase type 5 | - |
dc.subject.keywordAuthor | Udenafil | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.